AiM One HealthAiM One Health
Clinical Intelligence ← Back to site

See What Clinical Intelligence Looks Like

Sample Clinical Intelligence Reports

Explore representative AiM One reports showing how complex clinical and scientific questions are transformed into transparent, evidence-backed intelligence.

Start a Clinical Intelligence Request
This report is provided solely as a product demonstration and uses synthetic or de-identified information. It is not medical advice and must not be used to diagnose or treat any individual patient.
Synthetic data · demonstration only

Oncology Tumor Board Intelligence Report

Specialty: Medical Oncology Request type: Tumor Board Preparation Audience: Treating oncologist & tumor board
Evidence synthesisGuideline concordanceSpecialist deliberationRed-team challengeClinical trial matchingConfidence assessment
Cover

Case: 58-year-old (synthetic) with metastatic non–small cell lung cancer, adenocarcinoma, EGFR exon 19 deletion, PD-L1 TPS 40%. Question: evaluate evidence-supported first-line options and sequencing.

Table of Contents
  1. Executive Clinical Summary
  2. Case Synopsis & De-identification Note
  3. Evidence Synthesis (with citations)
  4. Multidisciplinary Deliberation
  5. Guideline Concordance
  6. Red-Team Challenge
  7. Clinical Trial Matching
  8. Confidence & Uncertainty Assessment
  9. Appendix: Evidence Library & Audit Trail
Executive Summary (excerpt)
For a treatment-naïve EGFR exon 19–deletion metastatic NSCLC, the council converges on a third-generation EGFR TKI as preferred first-line therapy, with the PD-L1 result not redirecting to front-line immunotherapy given the driver mutation. Two dissenting considerations — CNS surveillance cadence and the role of upfront local therapy for oligometastatic disease — are carried forward with explicit evidence…
Evidence Synthesis (excerpt)
[Pivotal RCT] In the referenced phase III trial, a third-generation EGFR TKI improved progression-free survival versus first-generation TKI in EGFR-mutated advanced NSCLC, with a favorable CNS activity profile. Synthetic citation for demonstration.
[Guideline] National guideline recommends EGFR-directed therapy over immunotherapy monotherapy in the presence of a sensitizing EGFR alteration, irrespective of PD-L1 expression. Synthetic citation for demonstration.
Red-Team Challenge (excerpt)
Challenge: "Does PD-L1 TPS 40% justify adding immunotherapy front-line?" Resolution: The consensus holds — in EGFR-driven disease, front-line immunotherapy is not supported and may raise toxicity risk when sequenced near TKIs. The recommendation is unchanged; the reasoning is documented.
Confidence & Uncertainty (excerpt)
HighStrong, guideline-concordant evidence for the first-line choice. Residual uncertainty: optimal CNS imaging interval and oligometastatic local therapy — flagged for the treating team.
This is a public preview. The full synthetic report includes the complete evidence library, full deliberation transcript, guideline scorecard, and audit trail.

Start a Similar Request